Beginner's Guide to GLP-1

WIKI · MAINTAINED BY THE MOD TEAM · UPDATED JUN 2026

Welcome to The GLP Lounge. This guide is the community's front door: a plain-English orientation to GLP-1 receptor agonists — semaglutide, tirzepatide, retatrutide and friends — plus the practical things every newcomer asks in their first week.

⚕ Not medical advice. The GLP Lounge is a community forum. Nothing on this page is a substitute for guidance from a licensed clinician. Always involve your prescriber before starting, stopping, or changing a medication.

Start with these resources

Trial Data Explorer

Visual summary of STEP, SURMOUNT, TRIUMPH and the cardiovascular outcome trials.

Dosing Calculator

Reconstitution math with a visual syringe — mg, mL, and insulin units.

Side Effects Guide

Real incidence data and evidence-based management for GI effects and beyond.

COA Verification

How to read a Certificate of Analysis and verify it directly with the lab.

Insurance Guide

Prior authorizations, appeals, savings programs and cost comparisons.

FAQ

Account questions, forum rules, posting etiquette and quick answers.

What are GLP-1 receptor agonists?

GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain. GLP-1 receptor agonists are engineered analogues that resist breakdown, so a single weekly injection produces steady receptor activation.

Newer molecules add receptors: tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide adds glucagon receptor activity on top — each addition has, so far, meant greater average weight reduction in trials.

−14.9%Semaglutide · STEP-1

−20.9%Tirzepatide · SURMOUNT-1

−24.2%Retatrutide · TRIUMPH-3

−20%MACE risk · SELECT

Want the full picture with curves and sources? Open the Trial Data Explorer.

A short history

2005

Exenatide (Byetta)

First GLP-1 agonist approved — twice-daily injection derived from Gila monster venom.

2014

Liraglutide (Saxenda)

First GLP-1 approved specifically for chronic weight management.

2017

Semaglutide (Ozempic)

Once-weekly dosing arrives; the modern era begins.

2021

Wegovy approval

Semaglutide 2.4 mg approved for obesity after STEP-1 showed ~15% mean weight loss.

2022

Tirzepatide (Mounjaro)

First dual GIP/GLP-1 agonist; SURMOUNT-1 reports ~21% mean weight loss.

2023–24

Zepbound & SELECT

Tirzepatide approved for obesity; SELECT shows a 20% cut in major cardiac events with semaglutide.

2025–26

Orals & triple agonists

Orforglipron phase 3 readouts and retatrutide's TRIUMPH program point at the next generation.

Your first 12 weeks — what to expect

Weeks 1–4 (starting dose): appetite quiets, "food noise" drops. Mild nausea is common — small meals, slow eating, hydration.
Weeks 4–8 (first titration): steady 0.5–1% body-weight loss per week is typical. Prioritize protein (1.2–1.6 g/kg) and resistance training to protect lean mass.
Weeks 8–12: most people settle into a rhythm. Track labs at baseline and ~3 months — see the Lab Results & Biomarkers forum for panels members actually order.
Plateaus are normal. Dose, sleep, protein and activity all matter more than day-to-day scale noise.

Where to post

Introduce yourself in the Public Square.
Drug-specific questions → Semaglutide, Tirzepatide, Retatrutide.
Sourcing questions are only allowed in vendor forums — read Buyer Beware first, and never trust a vendor without independent testing (how to verify).
Progress photos, DEXA scans and lab wins → Progress & Lab Results.

House rule #1: claims need sources. Posts that reference trials, COAs, or lab work earn the community's trust — "trust me bro" does not.